Lubiprostone for Treatment of Chronic Idiopathic Constipation

Summary

The purpose of this study was to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.

Timeline

Start

2016-04-14

Primary completion

2017-01-20

Completion

2017-02-24

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs Lubiprostone 24 μg; p = 0.007; Median Values of CI 1.0 (95% CI 0.1 to 1.9); Van Elteren Test NCT02695719 ↗

Drugs

Indications